Exploration and Validation of A Novel Inflammatory Response-Associated Gene Signature to Predict Osteosarcoma Prognosis and Immune Infiltration

Yucheng Fu
  Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital

Guoyu He
  Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital

Zhuochao Liu
  Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital

Jun Wang
  Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital

Zhusheng Zhang
  Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital

Qiyuan Bao
  Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital

Junxiang Wen
  Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital

Zhijian Jin
  Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital

Weibin Zhang (✉ zwb10368@rjh.com.cn)
  Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital
  https://orcid.org/0000-0003-3029-2924

Primary research

Keywords: osteosarcoma, inflammatory response, metastasis, prognosis, immune.

DOI: https://doi.org/10.21203/rs.3.rs-722434/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

Read Full License
Abstract

Background: Inflammatory response took part in the progression of tumor and was regarded as the hallmark of cancer. However, the prognostic relationship between osteosarcoma and inflammatory response-associated genes (IRGs) was unclear. This research aimed to explore the correlations between osteosarcoma prognosis and IRG signature.

Methods: The inflammatory response-associated differentially expressed messenger RNAs (DEmRNAs) were screened out through Gene Expression Omnibus (GEO) and Molecular Signature Database (MSigDB) databases. Univariate and multivariate cox regression analyses were utilized to construct the IRG signature. The prognostic value of signature was investigated through Kaplan–Meier (KM) survival curve and nomogram. DEmRNAs among high and low inflammatory response-associated risks were identified and functional enrichment analyses were conducted. ESTIMATE, CIBERSORT and single-sample gene set enrichment analyses (ssGSEA) were implemented to reveal the alterations in immune infiltration. All above results were validated in Target database. Quantitative real-time PCR (qRT-PCR) analysis was applied to detect the expression of the IRGs in human osteoblast and osteosarcoma cell lines.

Results: The IRG signature that consisted of two genes (MYC, CLEC5A) was established. In training and validation datasets, patients with lower risk scores lived longer and the IRG signature was confirmed as the independent prognostic factor in osteosarcoma. The nomogram was constructed and the calibration curves indicated the reliability of this model. Functional analysis of risk score-associated DEmRNAs showed that immune-related pathways and functions were significantly enriched. ssGSEA revealed that 14 immune cells and 11 immune functions were significantly dysregulated. The qRT-PCR results indicated IRGs were significantly differently expressed in osteosarcoma and osteoblast cell lines.

Conclusions: The novel osteosarcoma inflammatory response-associated prognostic signature was established and validated in this study. This model could serve as the biomarker and therapeutic target for osteosarcoma in the future.

1. Introduction

Osteosarcoma was the predominant malignant primary bone tumor which mainly occurred in adolescent. It was the second leading cause of tumor-associated death in teenagers[1, 2]. In order to overcome the lethality of osteosarcoma, the radical treatment which contained multi-drug neoadjuvant chemotherapy and aggressive surgical resection was applied in clinical. Since then, the 5-year survival rates of osteosarcoma patients had significantly improved[3]. However, numerous patients still developed metastasis before or after treatment and their survival rates dramatically decreased to less than 20%[4]. To improve the prognosis of these metastatic patients, novel therapeutic strategies such as immune checkpoint and molecular targeted inhibitors had been experimentally applied in clinical. Unfortunately, little progress had been achieved since the mechanism of metastasis was still elusive.
Inflammatory response, always accompanied with immune alterations in the tumor microenvironment, was involved in the development of tumor. It was first proposed by Virchow in 1863. He found that ‘lymphoreticular infiltrate’ was existed in the origin of tumor and this chronic inflammatory response might promote the progression of tumor[5]. After that, the relationships between inflammation and cancer were widely investigated. Some researchers regarded cancer as the wound that did not heal. The others demonstrated that chronic inflammatory response was the leading cause of gene mutations and epigenetic alterations, which promoted the malignancy of cancer cells[6, 7]. A large number of studies also revealed that some clinical blood inflammatory parameters were associated with the prognosis of cancers. In osteosarcoma, some elevated blood inflammatory-associated markers such as serum C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were related to decreased survival rates of patients[8, 9].

What’s more, with the advances in microarray and next-generation sequencing technology, numbers of inflammatory response-associated genes were discovered[10]. Several studies revealed that these genes could combine as the signature to predict the prognosis of patients with malignant tumors and they might be applied in clinic[11, 12]. However, few studies focused on the relationship between osteosarcoma and inflammatory response and no such signature had been established.

In the present study, we identified inflammatory response-associated differentially expressed messenger RNA (DEmRNA) related to osteosarcoma metastasis from Gene Expression Omnibus (GEO) database. Univariate cox regression analysis was conducted to screen out the prognosis-related genes and the prognostic signature was established through multivariate cox regression results. Next, patients were divided into low- and high-risk groups according to the median value of risk scores obtained previously. Then the Kaplan–Meier (KM) survival analysis was operated and the correlations between individual genes in signature and clinical features were explored. In addition, the nomogram was established and the immune infiltrative features of signature were investigated. All these prognostic features of signature were validated in Therapeutically Applicable Research to Generate Effective Treatments (Target) database. The DEmRNAs in signature were also validated in osteosarcoma and osteoblast cell lines. The flow chart of this study was shown in Figure 1. We believed that our research constructed a reliable gene signature to reveal the relationship between inflammatory response and osteosarcoma patients’ prognosis. We hoped that this signature could act as the novel prognostic biomarker and would be applied in clinical practice in the future.

2. Materials And Methods

2.1. Screening of datasets

The datasets of osteosarcoma patients were searched from Target (https://ocg.cancer.gov/programs/target) and GEO (http://www.ncbi.nlm.nih.gov/geo) databases. The inclusion criteria for dataset were shown as follows: (1) the patients were diagnosed as osteosarcoma by pathology; (2) the datasets should contain complete prognostic information; (3) the number of patients in
datasets should be more than 50. Finally, one GEO dataset (GSE21257, platform GPL10295, Illumina human-6 v2.0 expression beadchip Illumina, Inc., San Diego, CA, United States) was screened out as the training group and another dataset in Target database was selected as the validation group. The clinical characteristics of patients in two datasets were shown in Supplementary Table 1. The inflammatory response-associated genes were obtained from the hallmark gene sets in the Molecular Signature Database (MSigDB, https://www.gsea-msigdb.org/gsea/msigdb/).

2.2. Identification of inflammatory response-associated DEmRNAs

The mRNA expression file and patients’ clinical information were downloaded from each dataset. Patients in GSE21257 were separated into metastatic and non-metastatic groups and the DEmRNAs among these groups were screened out through Linear Models for Microarray Analysis (limma) package in R software. The cutoff values of screening were |fold change (FC)| > 1.5 and P < 0.05. The characteristic distribution of DEmRNAs was shown by ‘pheatmap’ package in R software. The inflammatory response-associated DEmRNAs were identified through overlapping DEmRNAs and inflammatory response-associated genes.

2.3. Construction and validation of the inflammatory response-associated prognostic signature

The inflammatory response-associated DEmRNAs related to osteosarcoma prognosis were identified by univariate cox regression analysis. The multivariate cox regression analysis was utilized to construct the inflammatory response-associated gene signature. The least amounts of DEmRNAs that represented the signature were screened through Akaike information criterion (AIC)[13]. The risk score of signature was calculated by the following formulation:

\[ \text{Risk score} = \sum_i \text{Coefficient}_{\text{mRNA}_i} \times \text{Expression}_{\text{mRNA}_i} \]

Then the patients in GSE21257 were divided into high- and low-risk groups according to the median value of risk score. The relationships between risk score and patients’ survival were conducted by KM survival curve in R software. The reliability of the signature was evaluated by time-related receiver operating characteristic (ROC) curves.

What’s more, the univariate and multivariate cox regression analyses were implied to evaluate the prognostic value of this gene signature. The correlations between individual mRNAs in signature and clinical features were explored through the follow-up information. The KM survival analysis of mRNAs in signature was also conducted. The above features of signature were validated in Target database and the KM survival analysis of individual mRNAs was examined in R2 database (https://hgserver1.amc.nl/cgi-bin/r2/main.cgi) once more. P < 0.05 was considered as statistically significant.

2.4. Establishment of the nomogram
Recently, the nomogram which contained patients’ clinical information was constructed to stratify the different risk patients in various studies [14]. The nomogram of the osteosarcoma patients in the present study was established through ‘rms’ package in R software. The predictive value of clinical factors such as gender, age and metastasis were calculated by multivariate cox regression analysis. The reliability of the nomogram was evaluated by Harrell’s concordance index (C-index). The nomogram was also established and validated in Target database.

2.5. Functional analyses of DEmRNAs related to inflammatory response-associated prognostic signature

The DEmRNAs related to this gene signature were screened out through high- and low-risk groups in Target and GSE21257 datasets. The overlapped DEmRNAs among these two datasets were considered as the risk score-related DEmRNAs. The heatmaps of DEmRNAs in two datasets were drawn by the ‘heatmap’ package in R software. The functional analyses of these DEmRNAs were performed by ‘clusterProfiler’ and ‘enrichplot’ packages in R software. P- and q-values less than 0.05 were defined as statistically significant.

2.6. Assessment of tumor immune infiltration status related to the inflammatory response

The infiltrative levels of immune and stromal cells in osteosarcoma samples were evaluated through immune and stromal scores by ESTIMATE software. The relationships between these scores and risk scores were conducted by Spearman correlate analysis[15]. Then the compositions of 22 immune cells in osteosarcoma were explored through the CIBERSORT deconvolution algorithm[16, 17]. In brief, the mRNA signature matrix of 22 immune cells was downloaded from the CIBERSORT platform (https://cibersortx.stanford.edu). Then it was matched with the mRNAs from GSE21257 and Target dataset to generate the infiltrative proportions of immune cells in osteosarcoma.

After that, the immune infiltrative differences between low- and high-risk patients were analyzed by single-sample gene set enrichment analysis (ssGSEA). The intersected differences with the same alternative trends in GSE21257 and Target datasets were regarded as the inflammatory response-associated immune changes in osteosarcoma.

2.7. Cell culture and reagents

Human osteosarcoma cell lines 143B, MNNG/HOS, SAOS2, U2OS, MG63 and human osteoblast cell line hFOB1.19 were obtained from ATCC (Manassas, VA, USA). Osteosarcoma cell line WELL5 was a kind gift from Dr. Wu Zhang of Shanghai Institute of Hematology[18]. All osteosarcoma cell lines were cultured in high glucose DMEM (Gibco,11965092) supplemented with 10% fetal bovine serum (FBS, Gibco,10099-141) and 1% penicillin-streptomycin (Gibco,15070063) at 37°C in 5% CO₂. The hFOB1.19 cell was cultured in DMEM/F12 medium (Gibco,11320033) containing 10% FBS and 0.3mg/ml G418 (Gibco,10131035) at 34°C in 5% CO₂.

2.8. Quantitative real-time PCR analysis
The mRNA expression of MYC and CLEC5A in osteosarcoma and osteoblast cell lines were quantified by quantitative real-time PCR (qRT-PCR) analyses. In brief, whole cellular RNA was extracted by Trizol reagent (Invitrogen, 15596018) and the cDNA templates were obtained by reverse transcription. The amplification was conducted through Roche LightCycler System. The whole procedure was performed according to the protocol of TB Green Premix Ex Taq II kit (Takara RR820A, Japan). The primer sequences of genes were: MYC: 5′- CGACGAGACCTTCATCAAAAAC-3′ (forward) and 5′-CTTCTCTGAGACGAGCTTGG-3′ (reverse); CLEC5A: 5′-GAAAAGGATCCACATTGGCAAT-3′ (forward) and 5′-GTCGCACAGTTGAAATTCTGA-3′; GAPDH: 5′-GCACCGTCAAGGCTGAGAAC-3′ (forward) and 5′-TGGTGAAGACGCCAGTGGA-3′. The expression of genes was calculated by formula $2^{-\Delta\Delta CT}$. The expressive difference between osteosarcoma and osteoblast cell lines or high- and low-metastatic osteosarcoma cell lines were calculated by Student’s t test. P value less than 0.05 was considered as statistically significant.

3. Results

1. Identification Of Inflammatory Response-associated Demnas Related To Osteosarcoma Metastasis

The mRNA expression matrix of GSE21257 which included 34 metastatic and 19 non-metastatic osteosarcoma patients were downloaded from GEO database. 247 up-regulated and 217 down-regulated DEmRNAs related to osteosarcoma metastasis were identified (Fig. 2A). Two hundred inflammatory response-associated genes were obtained from hallmark gene sets in MSigDB and then overlapped with previously obtained DEmRNAs (Fig. 2B). In the end, 24 inflammatory response-associated DEmRNAs were screened out (Table 1).
Table 1
The inflammatory response-associated DEmRNAs in GSE21257

| Gene       | Log$_2$FC | P Value   |
|------------|-----------|-----------|
| PDPN       | -0.72     | 0.041     |
| AXL        | -0.75     | 0.0079    |
| BST2       | -0.69     | 0.022     |
| C5AR1      | -0.62     | 0.00014   |
| STAB1      | -0.78     | 0.0021    |
| CXCL9      | -0.94     | 0.015     |
| TNFRSF1B   | -0.79     | 0.018     |
| CYBB       | -0.88     | 0.031     |
| CD48       | -0.82     | 0.00028   |
| CXCL10     | -1.26     | 0.0034    |
| LCP2       | -0.77     | 0.00060   |
| IL10RA     | -0.71     | 0.000084  |
| SERPINE1   | -0.77     | 0.023     |
| CLEC5A     | -0.90     | 0.0000013 |
| CCL5       | -0.79     | 0.0046    |
| OLR1       | -0.91     | 0.0012    |
| GNA15      | -0.77     | 0.0020    |
| IL1B       | -0.85     | 0.000077  |
| MYC        | 0.63      | 0.012     |
| PLAUR      | -0.80     | 0.00032   |
| CCL2       | -0.71     | 0.016     |
| RGS1       | -0.81     | 0.0090    |
| FPR1       | -0.82     | 0.00025   |
| CD14       | -1.29     | 0.000057  |

DEmRNA: differentially expressed messenger RNA
2. Construction and validation of the inflammatory response-associated prognostic signature in GEO and Target databases

Based on the 24 DEmRNAs acquired previously, univariate and multivariate cox regression analyses were utilized to establish the inflammatory response-associated prognostic signature. In univariate cox regression analysis, three genes were associated with osteosarcoma prognosis (Fig. 3A). Then two of these three DEmRNAs were screened out to construct the inflammatory response-associated prognostic signature according to the multivariate cox regression result (Table 2). The risk score formula was established through mRNAs’ regression coefficients multiplied by expression levels:

Table 2
The multivariate cox regression analysis of GSE21257

| Gene    | Coefficient | HR  | HR 95Low | HR 95High | P Value |
|---------|-------------|-----|----------|-----------|---------|
| CLEC5A  | -0.96       | 0.38| 0.18     | 0.83      | 0.015   |
| MYC     | 0.41        | 1.51| 0.92     | 2.49      | 0.11    |

Risk score= (0.41*MYC) + (-0.96*CLEC5A)

Based on the median value of risk score, 26 patients were assigned into high-risk group and the rest 27 were regarded as low-risk (Fig. 3B). At the same time, patients in high-risk group showed higher mortality rates and shorter survival time than low-risk patients (Fig. 3c). The KM survival curve also indicated worse survival rates existed in high-risk patients (Fig. 3D). Finally, the area under the time-dependent ROC curves (AUC) were 0.65 at 1-year, 0.80 at 3- and 5-year, which demonstrated the robustness of this inflammatory response-associated prognostic signature (Fig. 3E).

The reliability of the inflammatory response-associated gene signature was validated in Target database. Ninety-five patients with integrated follow-up information were included in the test. Based on the median value of risk scores, 48 patients were separated into low-risk group and the rest were considered as high risk (Fig. 3F). The risk plot (Fig. 3G) and KM survival analysis (Fig. 3H) showed that low-risk patients had better prognoses. In addition, the time-dependent ROC curve revealed the signature was robust (Fig. 3I).

3. Exploration of the relationship between clinical characters and inflammatory response-associated prognostic signature

The prognostic value of gene signature was investigated through univariate and multivariate cox regression analyses. Figure 4A and 4B showed that the risk score was the independent prognostic factor in osteosarcoma. The same result was validated in Target database. (Supplementary Fig. 1A and 1B).

After that, the correlations between clinical features and genes in signature were investigated. In GSE21257, CLEC5A and MYC were related to the metastasis status and inflammatory response-associated risk (Fig. 3E,3F,3I,3J). In Target database, CLEC5A and MYC were only correlated to risk scores
(Supplementary Fig. 1F and 1J). The KM survival analyses indicated the expression of CLEC5A positively related to the survival rates of osteosarcoma patients in GSE21257, Target and online R2 databases (Supplementary Fig. 2A,2C,2E). Instead, the higher expression of MYC related to the worse prognosis of osteosarcoma patients (Supplementary Fig. 2B,2D,2F).

4. Establishment of the nomogram

The nomogram was a powerful tool that integrated clinical variables to evaluate the prognosis of patients. In this research, the nomogram was constructed in GSE21257 and Target databases to predict the 3- and 5-year survival rates of osteosarcoma patients. (Figure 5A and Supplementary Figure 3A). The 3-year and 5-year calibration curves were close to the standard curve in two datasets (Figure 5B,5C and Supplementary Figure 3B,3C). The C-index was 0.99 in GSE21257 and 0.77 in Target dataset, which indicated the high accuracy of the predictive model.

5. Functional analysis of DEmRNAs related to inflammatory response-associated prognostic signature

The DEmRNAs among high- and low-risk patients were explored in GSE21257 and Target databases. A total of 736 DEmRNAs were screened out in GSE21257 and 1619 DEmRNAs were identified in Target database (Figure 6A and 6B). Then 216 DEmRNAs overlapped in two databases were selected for further analysis (Figure 6C).

The biological functions of these DEmRNAs were investigated through GO functional and KEGG pathway analyses (Figure 6D and 6E). A number of inflammatory response-associated biological processes such as neutrophil activation, regulation of leukocyte activation and antigen processing and presentation were significantly enriched. Furthermore, some immune-related functions (i.e., regulation of immune effector process, Th17 cell differentiation) were also enriched, which implied the potential relationships between inflammatory response and immune alterations in osteosarcoma.

6. Evaluation of the correlation between inflammatory response and immune infiltration

The relationship between tumor microenvironment and inflammatory response-associated risks was evaluated through ESTIMATE software. The results showed that the risk score was negatively related to the immune and stromal scores in GSE21257 and Target datasets (Figure 7A,7B and Supplementary Figure 4A,4B). Then the immune infiltration of 22 immune cells was investigated by CIBERSORT algorithm. The statistically significant abundance ratios of immune cells in osteosarcoma were shown in Figure 7C and supplementary Figure 4C. Then the specific relationships between immune functions and inflammatory response-associated risks were evaluated through ssGSEA analysis. The outcome revealed that the vast majority of immune cells (14) and functions (11) were down-regulated in high-risk group in GSE21257 (Figure 7D,7E). At the same time, eight immune cells and twelve immune functions were dysregulated in Target dataset (Supplementary Figure 4D,4E). The overlapped items including eight immune cells and eleven immune functions were considered as the alterations of inflammatory response-associated immune infiltration (Figure 7F).
7. Validation of the inflammatory response-associated genes in cell lines

The expressive levels of inflammatory response-associated genes in human osteosarcoma and osteoclast cell lines were detected through qRT-PCR analyses. The results showed that MYC was upregulated and CLEC5A was downregulated in all osteosarcoma cell lines (Figure 8A,8B). Then osteosarcoma cell lines were divided into high- (143B, WELL5, MNNG/HOS) and low-metastatic (U20S, SAOS2, MG63) groups according to their metastasis ability. The MYC was up-regulated in high-metastatic osteosarcoma cell lines and CLEC5A showed the opposite trend but with no statistically significant (Figure 8C,8D).

4. Discussion

Osteosarcoma, one of the most common bone malignant tumors, often developed lung metastasis and the 5-year survival rates of these patients were extremely low[2]. In clinical, the diagnosis of osteosarcoma metastasis mainly relied on the radiology tests such as X-ray, computerized tomography (CT) and positron emission tomography-computed tomography (PET-CT). Unfortunately, the sensitivity and specificity of these methods were not high enough and the patients with metastatic possibilities always lost the best chance to receive early treatment. Thus, the novel reliable evaluation criteria for early-stage metastasis were urgently needed.

In 1889, Paget first described the mechanism of tumor metastasis which was widely known as the ‘seed and soil’ theory[19]. After that, various theories related to metastasis were revealed, such as epithelial-mesenchymal transition (EMT), angiogenesis, gene mutation and so on[20]. Among these hallmarks, the inflammatory response was extensively investigated. Numerous inflammatory biomarkers, such as neutrophils, lymphocytes, platelets and so on, had been implied as the prognostic predictor for different cancers[21-23]. In osteosarcoma, some researchers revealed that lymphocyte-to-monocyte ratio (LMR) was positively related to overall and event-free survival rates of patients, while the neutrophil-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) showed the opposite trends[24-26]. Several studies also implied that nonsteroidal anti-inflammatory drugs (NSAIDs) could inhibit the progression of osteosarcoma[27, 28]. In addition, the relationship between inflammatory response-associated genes and osteosarcoma had also been widely studied. For instance, Jiang et al. found that the inflammatory gene polymorphisms were closely related to the occurrence and progression of osteosarcoma[29]. Recent researches also indicated that several inflammatory response-associated genes could combine as the prognostic signature in different cancers[11, 12]. However, none of this signature had been established in osteosarcoma.

In the present study, we first analyzed the relationship between osteosarcoma and inflammatory response-associated genes. We screened out 464 DEmRNAs related to osteosarcoma metastasis in GSE21257 dataset. By overlapping with MSigDB database, 24 of these DEmRNAs were identified as the inflammatory response-associated genes. Then two of these genes were selected to construct the inflammatory response-associated gene signature through univariate and multivariate cox regression
analyses. Next, patients in GSE21257 were separated into high- and low-risk groups according to the median value of risk scores. The KM survival curve indicated that the risk score was negatively correlated with patients’ survival rates and the AUC value of ROC curves revealed that this signature was reliable. Most importantly, the same results were obtained in Target database. Besides that, we verified that the risk score was the independent prognostic factor for osteosarcoma patients. The expression of individual mRNAs in the signature was related to the survival rates of patients in both datasets and R2 online database. What's more, qRT-PCR analyses revealed that the expression of MYC was up-regulated in all osteosarcoma cell lines while CLEC5A showed the opposite trend. Compared to low-metastatic cell lines, MYC was increased in high-metastatic cell lines but CLEC5A exhibited the contrary tendency. These experimental results revealed that the prognostic signature was reliable.

The nomogram was a convincible tool that incorporated clinical features to estimate the patients’ prognosis. It could stratify the patients with unfavorable prognoses and guide clinical treatments. In this research, the nomogram was established in both datasets and the calibration curves, as well as C indexes, indicating the robustness of this nomogram. To sum up, we believed that this inflammatory response-associated gene signature was a reliable prognostic predictor for osteosarcoma and it could be easier to apply in clinics because only two genes were involved in it.

Next, we screened out the overlapped DEmRNAs related to inflammatory response-associated risks in GSE21257 and Target datasets. The functional analyses of these genes indicated that they were involved in the dysregulated immune functions such as regulation of immune effector process, Th17 cell differentiation and so on. According to the above results, we speculated that the inflammatory response might transform the tumor microenvironment, especially for immune system. We then used Estimate algorithm to evaluate the correlation between inflammatory response-associated risks and stromal or immune infiltration. Both stromal and immune scores were negatively related to risk scores, which indicated higher purity of osteosarcoma cells existed in high-risk groups. This implied that high-risk osteosarcoma was poorly immunogenic infiltrated, which was widely known as immunologically cold tumors and thus was not sensitive to immunogenic therapy[30]. To further investigate the specific dysregulation of immune functions, ssGSEA analysis was conducted. The results showed that high-risk patients related to decreased infiltrative immune cells and functions. These conclusions were validated in various studies. For example, Muraro et al. found that osteosarcoma cells could inhibit the maturation and functions of dendritic cells (DCs) and these effects would be reversed by adding inflammatory-associated cytokines (rhIL-12) or compounds (Indometacin)[31]. The follicular helper T (Tfh) cells were related to the prognosis of patients in several tumors[32]. Gao et al. revealed that impaired functions of Tfh lead to lower IL-21 secretion in CD4+ T cells, which might result in the immunosuppressive microenvironment in osteosarcoma patients[33]. In a word, the inflammatory response was closely related to the osteosarcoma immune infiltrative alteration and the down-regulated immune functions might be the reason for tumor development.

What’s more, the mRNAs in our inflammatory response-associated signature also played vital roles in tumor progression. MYC, one of the most common oncogene, was mutated in more than 10% of
osteosarcoma patients[34]. High expression of MYC promoted proliferation, migration and spheroid formation of osteosarcoma cells and it was also upregulated in metastatic samples[35, 36]. In addition, Kortlever et al. revealed that Myc promoted the inflammatory, angiogenic and immunosuppressive tumor microenvironment by elevating IL-23 and CCL9, which accelerated pulmonary tumor progression. C-type lectin domain family 5 member A (CLEC5A) was one of the C-type lectin receptors that involved in inflammatory diseases[37]. It regulated the release of pro-inflammatory cytokines from macrophages during infection and was involved in the process of collagen-induced arthritis[38]. It played vital roles in the innate immune system through regulating the differentiation and activation of macrophages as well as neutrophils [39]. Lu et al. found that the expression of CLEC5A in osteosarcoma was higher than adjacent normal tissues and it could prevent the metastasis of osteosarcoma[40]. However, the specific mechanisms of CLEC5A in osteosarcoma progression were still unknown and further research should be carried out.

For all we know, this research first revealed the relationship between inflammatory-associated gene signature and osteosarcoma prognosis. However, several defects still remained. First, the sample size of datasets was relatively small. This might owe to the extremely low incidence of osteosarcoma and the large cohort researches in osteosarcoma were limited. Second, the correlations between immune infiltration and gene signature might be variable because osteosarcoma was high heterogeneity. Most importantly, our research was a retrospective study and the result should be verified in other prospective studies in the future.

5. Conclusion

In conclusion, our study constructed and validated the inflammatory response-associated gene signature related to osteosarcoma prognosis. What’s more, we provided novel insights into the relationship between immune infiltration and inflammatory response. This signature could be regarded as the prognostic biomarkers for osteosarcoma and acted as the therapeutic targets in clinical. Further basic and clinical studies should be conducted to illuminate the precise mechanisms of inflammatory response in osteosarcoma.

Declarations

Fundings

This work was supported by the National Natural Science Foundation of China (NSFC, NO. 81702661,82072957).

Availability of data and materials

The datasets used in this study were available at Target (https://ocg.cancer.gov/programs/target) and GEO (http://www.ncbi.nlm.nih.gov/geo) databases.
Acknowledgments

We appreciated researchers and patients particated in GEO and Target datasets.

Authors’ contributions

YCF and WBZ designed the study. ZSZ and QYB searched the data from database. YCF, JXW and QYB performed analysis of the data in silico. YCF and ZCL wrote the manuscript. JW and ZJJ revised the manuscript. GYH modified language. All authors had read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

All authors were agreed to publish this research.

Competing interests

All authors have no conflicts of interest to declare.

References

1. Beck O, Paret C, Russo A, Burhenne J, Fresnais M, Steimel K, Seidmann L, Wagner DC, Vewinger N, Lehmann N et al: Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma. Cancers 2020, 12(4).

2. Ritter J, Bielack SS: Osteosarcoma. Annals of oncology : official journal of the European Society for Medical Oncology 2010, 21 Suppl 7:vii320-325.

3. Anderson ME: Update on Survival in Osteosarcoma. The Orthopedic clinics of North America 2016, 47(1):283-292.

4. Kansara M, Teng MW, Smyth MJ, Thomas DM: Translational biology of osteosarcoma. Nature reviews Cancer 2014, 14(11):722-735.

5. Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet (London, England) 2001, 357(9255):539-545.

6. Sipos F, Fimeisz G, Műzes G: Therapeutic aspects of c-MYC signaling in inflammatory and cancerous colonic diseases. World journal of gastroenterology 2016, 22(35):7938-7950.

7. Dvorak HF: Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. The New England journal of medicine 1986, 315(26):1650-1659.

8. Jettoo P, Tan G, Gerrand CH, Rankin KS: Role of routine blood tests for predicting clinical outcomes in osteosarcoma patients. Journal of orthopaedic surgery (Hong Kong) 2019, 27(2):2309499019838293.
9. Li X, Tian F, Wang F, Li Y: Serum C-reactive protein and overall survival of patients with osteosarcoma. *Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine* 2015, 36(7):5663-5666.

10. Diakos CI, Charles KA, McMillan DC, Clarke SJ: Cancer-related inflammation and treatment effectiveness. *The Lancet Oncology* 2014, 15(11):e493-503.

11. Lin Z, Xu Q, Miao D, Yu F: An Inflammatory Response-Related Gene Signature Can Impact the Immune Status and Predict the Prognosis of Hepatocellular Carcinoma. *Front Oncol* 2021, 11:644416.

12. Zhang C, Zhang Z, Zhang G, Zhang Z, Luo Y, Wang F, Wang S, Che Y, Zeng Q, Sun N et al: Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma. *Cancer Lett* 2020, 479:31-41.

13. Vrieze SI: Model selection and psychological theory: a discussion of the differences between the Akaike information criterion (AIC) and the Bayesian information criterion (BIC). *Psychological methods* 2012, 17(2):228-243.

14. Iasonos A, Schrag D, Raj GV, Panageas KS: How to build and interpret a nomogram for cancer prognosis. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology* 2008, 26(8):1364-1370.

15. Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA et al: Inferring tumour purity and stromal and immune cell admixture from expression data. *Nature communications* 2013, 4:2612.

16. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA: Robust enumeration of cell subsets from tissue expression profiles. *Nature methods* 2015, 12(5):453-457.

17. Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA: Profiling Tumor Infiltrating Immune Cells with CIBERSORT. *Methods in molecular biology (Clifton, NJ)* 2018, 1711:243-259.

18. Zhang W, Zhao JM, Lin J, Hu CZ, Zhang WB, Yang WL, Zhang J, Zhang JW, Zhu J: Adaptive Fibrogenic Reprogramming of Osteosarcoma Stem Cells Promotes Metastatic Growth. *Cell reports* 2018, 24(5):1266-1277.e1265.

19. Fokas E, Engenhart-Cabiliic R, Daniilidis K, Rose F, An HX: Metastasis: the seed and soil theory gains identity. *Cancer Metastasis Rev* 2007, 26(3-4):705-715.

20. Han Y, Guo W, Ren T, Huang Y, Wang S, Liu K, Zheng B, Yang K, Zhang H, Liang X: Tumor-associated macrophages promote lung metastasis and induce epithelial-mesenchymal transition in osteosarcoma by activating the COX-2/STAT3 axis. *Cancer Lett* 2019, 440-441:116-125.

21. Dai Y, Liu M, Lei L, Lu S: Prognostic significance of preoperative prognostic nutritional index in ovarian cancer: A systematic review and meta-analysis. *Medicine* 2020, 99(38):e21840.

22. Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, Seruga B, Ocaña A, Tannock IF, Amir E: Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. *Cancer epidemiology, biomarkers & prevention: a publication of the*
American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2014, 23(7):1204-1212.

23. Gu L, Li H, Chen L, Ma X, Li X, Gao Y, Zhang Y, Xie Y, Zhang X: Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis. Oncotarget 2016, 7(22):31926-31942.

24. Liu T, Fang XC, Ding Z, Sun ZG, Sun LM, Wang YL: Pre-operative lymphocyte-to-monocyte ratio as a predictor of overall survival in patients suffering from osteosarcoma. FEBS open bio 2015, 5:682-687.

25. Liu B, Huang Y, Sun Y, Zhang J, Yao Y, Shen Z, Xiang D, He A: Prognostic value of inflammation-based scores in patients with osteosarcoma. Scientific reports 2016, 6:39862.

26. Xia WK, Liu ZL, Shen D, Lin QF, Su J, Mao WD: Prognostic performance of pre-treatment NLR and PLR in patients suffering from osteosarcoma. World journal of surgical oncology 2016, 14:127.

27. Zuckerman LM, Frames WL, Elsissy JG, Shields TG, de Necochea-Campion R, Mirshahidi HR, Williams NL, Mirshahidi S: The effect of non-steroidal anti-inflammatory drugs on osteosarcoma cells. European review for medical and pharmacological sciences 2019, 23(6):2681-2690.

28. Liu B, Yan S, Qu L, Zhu J: Celecoxib enhances anticancer effect of cisplatin and induces anoikis in osteosarcoma via PI3K/Akt pathway. Cancer cell international 2017, 17:1.

29. Jiang Y, Wang X, Cheng Y, Peng J, Xiao J, Tang D, Yi Y: Associations between inflammatory gene polymorphisms (TNF-α 308G/A, TNF-α 238G/A, TNF-β 252A/G, TGF-β1 29T/C, IL-6 174G/C and IL-10 1082A/G) and susceptibility to osteosarcoma: a meta-analysis and literature review. Oncotarget 2017, 8(57):97571-97583.

30. Sharma P, Allison JP: The future of immune checkpoint therapy. Science (New York, NY) 2015, 348(6230):56-61.

31. Muraro M, Mereuta OM, Saglio F, Carraro F, Berger M, Madon E, Fagioli F: Interactions between osteosarcoma cell lines and dendritic cells immune function: An in vitro study. Cellular immunology 2008, 253(1-2):71-80.

32. Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G et al: CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. The Journal of clinical investigation 2013, 123(7):2873-2892.

33. Gao W, Zhou J, Ji B: Evidence of Interleukin 21 Reduction in Osteosarcoma Patients Due to PD-1/PD-L1-Mediated Suppression of Follicular Helper T Cell Functionality. DNA and cell biology 2017, 36(9):794-800.

34. Ueda T, Healey JH, Huvos AG, Ladanyi M: Amplification of the MYC Gene in Osteosarcoma Secondary to Paget's Disease of Bone. Sarcoma 1997, 1(3-4):131-134.

35. Chen D, Zhao Z, Huang Z, Chen DC, Zhu XX, Wang YZ, Yan YW, Tang S, Madhavan S, Ni W et al: Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma. Bone research 2018, 6:11.
36. Han G, Wang Y, Bi W: C-Myc overexpression promotes osteosarcoma cell invasion via activation of MEK-ERK pathway. *Oncology research* 2012, 20(4):149-156.

37. Xiong W, Wang H, Lu L, Xi R, Wang F, Gu G, Tao R: The macrophage C-type lectin receptor CLEC5A (MDL-1) expression is associated with early plaque progression and promotes macrophage survival. *Journal of translational medicine* 2017, 15(1):234.

38. Chen X, Eksioglu EA, Carter JD, Fortenbery N, Donatelli SS, Zhou J, Liu J, Yang L, Gilvary D, Djeu J et al: Inactivation of DAP12 in PMN inhibits TREM1-mediated activation in rheumatoid arthritis. *PloS one* 2015, 10(2):e0115116.

39. Huang YL, Chen ST, Liu RS, Chen YH, Lin CY, Huang CH, Shu PY, Liao CL, Hsieh SL: CLEC5A is critical for dengue virus-induced osteoclast activation and bone homeostasis. *Journal of molecular medicine (Berlin, Germany)* 2016, 94(9):1025-1037.

40. Lu J, Chen W, Liu H, Yang H, Liu T: Transcription factor CEBPB inhibits the proliferation of osteosarcoma by regulating downstream target gene CLEC5A. *Journal of clinical laboratory analysis* 2019, 33(9):e22985.

Figures
Figure 1

The flow chart of the present study. (A). The osteosarcoma inflammatory response-associated DEmRNAs were identified in GSE21257 and MSigDB databases. (B). The inflammatory response-associated gene signature was established through univariate and multivariate cox regression analyses. (C). The application of inflammatory response-associated gene signature in clinic and validation in Target database. (D). Identification and functional analysis of DEmRNAs related to inflammatory response-
associated risk. (E). The association between immune infiltration and inflammatory response. DEmRNA: differentially expressed messenger RNA.

Figure 2

Identification of inflammatory response-associated DEmRNAs related to osteosarcoma metastasis. (A) DEmRNAs related to osteosarcoma metastasis in GSE21257 database. Red dots indicated up-regulated DEmRNAs (P < 0.05, FC > 1.5) and green dots indicated down-regulated DEmRNAs (P > 0.05, FC < -1.5). (B) Twenty-four inflammatory response-associated DEmRNAs were screened out in GSE21257 and MSigDB databases. DEmRNA, differentially expressed messenger RNA; FC, fold change; MSigDB: Molecular Signature Database.
Construction and validation of the inflammatory response-associated prognostic signature in GSE21257 and Target datasets. (A) Three inflammatory response-associated prognostic genes were identified in univariate cox regression analysis. (B, F) The distribution and median value of risk scores in GSE21257 (B) and Target (F) datasets. (C, G) The scatter plot of patients’ risk scores and survival status in GSE21257 (C) and Target (G) datasets. (D, H) Kaplan-Meier survival plot of patients in high- and low-risk groups in GSE21257 (D) and Target (H) datasets. (E, I) Time-dependent ROC curve at 1, 3, and 5 years of apoptosis-associated prognostic signature in GSE21257 (E) and Target (I) datasets. ROC, receiver operating characteristic.
Figure 4

Relationships between inflammatory response-associated gene signature and clinical parameters in GSE21257. (A, B). Univariate and multivariate cox regression analyses revealed the risk score was the independent prognostic factor in GSE21257. (C-F). Boxplots of the relationship between CLEC5A expression and clinical characteristics. (G-J). The correlation between MYC expression and clinical characteristics. CLEC5A: C-type lectin domain family 5 member A.

CLEC5A: C-type lectin domain family 5 member A.
Figure 5

Establishment of the nomogram in GSE21257. (A) The nomogram predicted the 3- and 5-year survival risk in osteosarcoma patients. (B) The calibration curve of the 3-year survival. (C) The calibration curve of the 5-year survival.
Figure 6

Identification and functional analyses of DEmRNAs related to inflammatory response-associated risks. (A) The heatmap of DEmRNAs associated with risk score in GSE21257. (B) The heatmap of risk score-associated DEmRNAs in Target dataset. (C) The overlapped DEmRNAs in GSE21257 and Target datasets. (D, E) The top 10 GO functional and top 30 KEGG pathway analyses of DEmRNAs. DEmRNA: differentially expressed messenger RNA; GO, gene ontology; KEGG, Kyoto encyclopedia of genes and genomes.
Figure 7

The relationships between inflammatory response and immune infiltration in GSE21257. (A) The correlation between risk score and immune score. (B) The relationship between risk score and stromal score. (C) The infiltrative proportion of 22 immune cells in osteosarcoma with statistically significant. (D) The correlations between risk scores and different immune cells. (E) The association between risk scores and different immune functions. (F) The overlapped immune cells and functions in GSE21257 and Target datasets. NS, not significant; *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 8

The expression of MYC and CLEC5A in cell lines. A and B. The expression of MYC and CLEC5A in osteosarcoma and osteoblast cell lines. C and D. The expression of MYC and CLEC5A in high- and low-metastatic cell lines. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SUPPFigure1.jpg
- SuppFigure2.jpg
- SuppFigure3.jpg
- SuppFigure4.jpg
- Supple.doc